Gland Pharma Profit & Loss Annual

Trade
BSE: 543245 | NSE: GLAND | ISIN: INE068V01023 | Sector: Biotechnology & Drugs
1,785.00 +28.45 (1.62%)Updated : 25 Nov 2024
Fiscal Period2024202320222021
Period End DateMar 24Mar 23Mar 22Mar 21
Revenue 5,664.723,624.604,400.713,462.88
Total Revenue 5,664.723,624.604,400.713,462.88
Costof Revenue Total 2,173.091,733.322,149.331,538.17
Gross Profit 3,491.631,891.282,251.381,924.70
Selling/ General/ Admin Expenses Total 1,486.88810.00694.61590.16
Depreciation/ Amortization 344.57146.74110.3098.78
Unusual Expense( Income) 0.0062.79--
Other Operating Expenses Total 671.689.733.790.12
Total Operating Expense 4,676.222,802.953,000.672,259.43
Operating Income 988.51821.651,400.031,203.45
Interest Inc( Exp) Net- Non- Op Total -262.002,331.232,189.371,235.64
Other Net 170.24-0.11-0.247.78
Net Income Before Taxes 1,132.541,054.581,618.551,334.81
Provisionfor Income Taxes 360.08273.54406.89337.85
Net Income After Taxes 772.46781.041,211.66996.96
Net Income Before Extra Items 772.46781.041,211.66996.96
Net Income 772.46781.041,211.66996.96
Income Availableto Com Excl Extra Ord 772.46781.041,211.66996.96
Income Availableto Com Incl Extra Ord 772.46781.041,211.66996.96
Diluted Net Income 772.46781.041,211.66996.96
Diluted Weighted Average Shares 16.4716.4716.4515.83
Diluted EPS Excluding Extra Ord Items 46.8947.4373.6462.99
DPS- Common Stock Primary Issue 20.00---
Diluted Normalized EPS 46.8950.2673.6562.99
Research Development -403.77426.56321.99
Gain( Loss)on Saleof Assets --0.81-1.780.24
*All figures in crores except per share values
Recommended For You
Trending Stocks
3,753.25+148.70(4.13%)
1,784.60+38.65(2.21%)
1,733.95-13.75 (-0.79%)
2,460.60-18.40 (-0.74%)
HomeMarketsPremiumInstant LoanMint Shorts